Project Grant R50CA293827
Award Date 8/7/25
Completion Date 7/31/30
Dollars Obligated $120K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Miami to support research into a novel immunotherapy approach for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a can regulate T cell exhaustion and restore anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC), which has a very low 5-year survival rate of 12%. The research will utilize the KPC mouse model of PDAC...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- The federal Project Grant award of $268,345 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel immunotherapy for pancreatic cancer. The primary awardee, Sanford Burnham Prebys Medical Discovery Institute, will investigate the PSGL-1/VISTA axis as a potential target for boosting the anti-tumor immune response in pancreatic tumors. This 2-year project, with a start date of Mar 10, 2025 and end date of Feb 28, 2027, aims to elucidate...
- This $156,276 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program. The funding supports research aimed at decoding therapeutic tumor antigens and understanding how dendritic cells contribute to anti-tumor T cell immunity, with a focus on pancreatic cancer. Key objectives include comparing tumor immunopeptidomes presented by cancer cells versus dendritic cells, and evaluating the impact of regulatory T cells on...
- This $113,937 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, is funding research to identify methods for harnessing the potential of "bystander" T cells to develop new cancer immunotherapies. The project aims to explore how bystander T cells, which are not specific to tumor antigens, can be activated within the tumor microenvironment to...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This $151,263 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program to fund a research project titled "Understanding Paracrine Interactions Induced by Morphogens in PDAC" at The Trustees of Columbia University in the City of New York. The project aims to identify how active morphogen signaling shapes local immunosuppression in the pancreatic tumor microenvironment by studying the interactions between malignant...
- This $410,115 Project Grant was awarded by the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), to the University of California, San Diego (UC San Diego) to support research aimed at improving preclinical models of metastatic pancreatic cancer. The research project seeks to understand how the collagen-rich tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) drives metastasis and treatment resistance, and to develop a synthetic 3D high density...
- The Project Grant award of $1,146,618 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mucommune LLC, a biopharmaceutical company in Morrisville, NC. The grant supports the development of in vivo-engineered CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma. Specifically, the project aims to leverage Mucommune's proprietary platform that can efficiently transduce non-activated T cells with chimeric antigen receptors (CARs)...